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Introduction: In many patients with rheumatoid arthritis (RA) subclinical disease activity can be detected with
ultrasound (US), especially using power Doppler US (PDUS). However, PDUS may be highly dependent on the type
of machine. This could create problems both in clinical trials and in daily clinical practice. To clarify how the PDUS
signal differs between machines we created a microvessel flow phantom.
Methods: The flow phantom contained three microvessels (150, 1000, 2000 microns). A syringe pump was used to
generate flows. Five US machines were used. Settings were optimised to assess the lowest detectable flow for each
US machine.
Results: The minimal detectable flow velocities showed very large differences between the machines. Only two of
the machines may be able to detect the very low flows in the capillaries of inflamed joints. There was no clear
relation with price. One of the lower-end machines actually performed best in all three vessel sizes.
Conclusions: We created a flow phantom to test the sensitivity of US machines to very low flows in small vessels.
The sensitivity of the power Doppler modalities of 5 different machines was very different. The differences found
between the machines are probably caused by fundamental differences in processing of the PD signal or internal
settings inaccessible to users. Machines considered for PDUS assessment of RA patients should be tested using a
flow phantom similar to ours. Within studies, only a single machine type should be used.Introduction
Rheumatoid arthritis (RA) is a common disease with a
prevalence of around 1% worldwide [1]. RA is poten-
tially an invalidating disease [2], but early diagnosis in
the so-called window of opportunity [3,4] and treatment
according to a treat-to-target protocol [5] can optimise
the outcome for RA patients. Adding ultrasound (US)
to the diagnostic workup and monitoring of treatment
may provide even better results. In rheumatological US
both greyscale and power Doppler (PD) are used, of
which PDUS seems to have the largest value. PDUS has
the potential to reclassify patients to a higher joint
group according to the 2010 classification criteria for
RA, increasing the risk for undifferentiated arthritis to* Correspondence: d.tencate@erasmusmc.nl
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reproduction in any medium, provided the orbe definite RA [6]. Furthermore, the presence of PDUS
inflammation in joints that are not swollen at clinical
examination has shown to be clinically relevant in pa-
tients in remission of RA, since it predicts occurrence
of flare and erosive progression [7-10]. Correct assess-
ment of the presence and absence of a PD signal indica-
ting the presence of inflammation is therefore vital in
rheumatological US.
However, PDUS may be highly dependent on the type
of US machine used [11,12]. We also observed this in
our centre (see Figure 1).
If there are indeed large differences in the performance
of PDUS per machine, the choice of machine might be
essential for a valid detection of inflammation. Using dif-
ferent machines within a multi-machine study or during
patient treatment could then have a detrimental impact
on treatment decisions or study outcome.al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Different performance of the power Doppler
ultrasound modality of two machines in one patient.
(A) Machine B, presence of a positive power Doppler signal (arrow)
within the region of synovial proliferation. (B) Machine A, this signal
is absent. Arrowhead, vessel; *noise on cortical surface.
Figure 2 Flow phantom with a fixated probe. BMF,
blood-mimicking fluid.
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of different machines in an objective way, we decided to
perform an in vitro experiment. To compare the PD
function of different US machines one could use a flow
phantom. This flow phantom should mimic the tissue
that is scanned by PDUS in rheumatology; that is, very
small vessels and very low flows. To our knowledge, no
studies have been conducted investigating the size of
capillaries and the blood flow velocity in an inflamed
joint, but there are data on capillaries in healthy sub-
jects’ nailfolds and capillaries in periulcerous regions.
These capillaries have a diameter of around 30 μm and
the blood flow velocity can be as low as 0.5 mm/second
[13,14]. Flow phantoms previously presented did not
compare US machines [15], used vessels that were con-
siderably larger than capillaries, or assessed many capil-
laries close to each other at once, making it impossible
to evaluate the flow velocity in the individual vessels
[11,12,16,17]. For these reasons, we created a new flow
phantom with a very small, single vessel to obtain the
lowest detectable flow velocity of five US machines. Two
additional larger vessels were included in the phantom
for comparison with the literature [11,12].
Methods
Phantom
The flow phantom (Figure 2) consisted of an acrylic
(polymethyl methacrylate) container filled with tissue-
mimicking material, according to a previously published
recipe [18]. In this tissue-mimicking material we placed
three microvessels: 150 μm (inner diameter) vessel
made of polyethylene terephthalate glycol-modified
(Paradigm Optics, Vancouver, WA, USA), and 2,000 μm
and 1,000 μm (inner diameter) vessels made of silicone(Eriks bv, Alkmaar, the Netherlands). These two vessels
were included to compare our phantom with already
published studies [11,12]. Initially we used vessels with
diameters of 50 μm and 100 μm also made of polye-
thylene terephthalate glycol-modified, but these were
blocked almost instantly. The blood-mimicking fluid
(BMF) was based on the recipe by Ramnarine and
colleagues [19]. Briefly, 91.07% (w/w) demineralised
water, 1.18% (w/w) dextran (average 150 kDa, D4876;
Sigma-Aldrich, Zwijndrecht, the Netherlands), 0.90%
(w/w) ICI supersonic N surfactant, 5.03% (w/w) glycerol,
and 1.82% w/w orgasol particles (5 μm in diameter; Arkema
B.V., Rotterdam, The Netherlands) were mixed using a
magnetic stirrer. The BMF was then filtered using a 40 μm
sieve (352340; BD, Breda, the Netherlands) and degassed
using a vacuum pump. Compared with the original recipe
by Ramnarine and colleagues, our BMF contained half the
amount of dextran and glycerol – this made our BMF less
viscous, which was necessary to prevent blockage of the
vessels. A syringe pump (Hugo Sachs Elektronik, March-
Hugstetten, Germany) was used to generate flows. This
pump can produce regular flows as low as 1.28 pl/minute.
For each vessel size, flow settings (ml/hour) were calculated
that corresponded to average flow velocities ranging from
40 to 0.005 mm/second, using the following equation,
where Q is flow (m3/second), Vavg is the average flow
velocity (m/second) and R is the radius (m):
Q ¼ Vavg  πR2
The actual volume transported through the vessels
was tested by turning on the pump, and completely
filling the vessel until drops of BMF came out of the
capillary. A complete number of drops were captured in
a container while recording the time. This container was
Table 1 Machines tested (alphabetical order) and
probes used
Machine A Aloka Ltd., Tokyo, Japan α7 (probe UST-5411)
Machine B Esaote, Maastricht, the Netherlands MyLab60
(probe LA 435)
Machine C Philips Healthcare, Amsterdam, the Netherlands iU22
(probe L9-3)
Machine D Ultrasonix Medical Corporation, Vancouver, Canada
(probe L14-5/38)
Machine E VisualSonics, Toronto, Canada Vevo2100
(probe MS200)
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balance. With the relative density of the BMF we calcu-
lated the flow (transported volume per time).
Experiment
The lowest detectable flow for each machine/vessel
diameter combination was defined as the flow that still
resulted in a continuous PDUS signal (Figure 3). First
the pump was set to a high flow, and then gradually
decreased in steps until a continuous PD signal could
just still be detected. The value of the lowest flow was
recorded. Between each change of pump flow we waited
5 minutes for the system to reach stable flow velocities.
For each lowest detectable flow per vessel we stored an
image and recorded the machine settings used to acquire
this image.
Ultrasound machines and settings
Five available US machines were tested (Table 1). Machines
A and B are used in our Department of Rheumatology in
daily clinical practice. Machine C is a high-end machine
for general imaging. Machines D and E are specialised
research machines, the latter a highly specialised machine
for high-frequency small animal imaging. Four machines
operated at or around the most common frequency of
10 MHz (Machines A, B, D and E), and one (Machine C)
operated lower at a frequency between 3 and 9 MHz
(actual frequency not displayed on this machine). Settings
on all machines were optimised to detect lowest flows by
adjusting pulse repetition frequency (PRF)/velocity range,
wall filters, Doppler frequency and Doppler gain. In
general this meant for all vessels using the lowest wall
filter, the lowest velocity range or PRF and the highest
suitable Doppler gain with respect to noise level. One
experienced musculoskeletal ultrasonographer (DFTC)
performed all US examinations.Figure 3 Continuous PDUS signal in a 1 mm vessel on
Machine B.Results
We found that the pump was accurate enough for our
purposes, especially when taking into account the very
low flows used (see Table 2). The lowest detectable flow
velocities in the different vessels are presented in Table 3.
These differed very much, by a factor of 100 between
machines. This was the case for all vessel sizes. In the
smallest vessel (150 μm), which most resembles the situ-
ation in an inflamed joint, two machines (Machines D
and E) could not detect a positive PD signal at all at any
flow velocity. For the other vessels, the minimal detec-
table velocity ranged from 0.11 mm/second (Machine B)
to 11.1 mm/second (Machine A). The settings were
optimised for the detection of lowest flow. See Table 4
for the settings of PRF/velocity range, wall filter and
Doppler frequency per machine for the smallest vessel.
Discussion
We showed that the sensitivity of the PD modalities of five
US machines (three machines used in the clinic and two
used for research) was very different, using a microvessel
flow phantom. The very large differences found between
the machines are only partly explained by each machine’s
Doppler frequency, lower limits of PRF and wall filter
settings, but are most probably caused mainly by funda-
mental differences in processing the PD signal or internal
settings inaccessible to users. There was no clear relation
with price or technical sophistication of the machines:
a lower-end machine (Machine B) performed best for
all three vessels, while mid-range and high-end research
machines (Machines D and E) did not detect any flow in
the smallest vessel, against expectations.
Only one machine of the five (Machine B) could detect
the low flow velocity in capillaries that based on previous
research are estimated to be between 0.5 and 1 mm/second.
Machine C came close to this limit, which underlines
our conclusion that the observed differences are mainly
caused by differences in processing of the signal, since the
probe that was available for Machine C had a bandwidth
of only 3 to 9 MHz. When a high-frequency probe would
have been used with this machine, it might also have been
able to detect flow less than 1 mm/second in the smallest
Table 2 Measuring the reliability of the pump
2,000 μm vessel 1,000 μm vessel 150 μm vessel 150 μm vessel 150 μm vessel
Set flow 11.31 3.142 0.141 0.070 0.035
Measured flow 10.68 2.948 0.276 0.108 0.049
Flow (ml/hour).
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according to this limit.
As mentioned above, flow phantoms have been published
in the literature before [11,12,15-17]. However, when com-
paring the PD modalities of different US machines it is es-
sential to use small, individual vessels. A positive PD signal
depends on the total detected Doppler signal power within
the range gate (the colour Doppler pixel size, typically
<1 mm). This power depends on the number of particles
that have a velocity above a certain threshold. This thresh-
old is determined by the wall filter, the PRF/velocity range.
Whether a PD signal is actually detected/displayed is also
dependent on the noise level of the system and the system’s
ability to suppress clutter and signal from stationary targets.
If the vessel diameter is larger than the gate size, the
velocity threshold will determine the lowest detectable
velocity. This explains why the minimum velocities found
for 1 and 2 mm vessels are similar.
However, if the velocity is the same but the vessel is
much smaller than the gate size, the number of moving
particles will be lower and more stationary tissue will be
inside the gate range. The tissue suppression and noise
level then become more important and the minimal de-
tectable velocity will be raised. This means that a phan-
tom with a vessel too large in diameter [11,12] may use
a flow velocity similar to that in vessels in an inflamed
joint, but more particles are inside one pixel in the
phantom situation (in vitro) compared with the situation
in an inflamed joint (in vivo). This can possibly cause a
positive PD signal based on the large number of par-
ticles. In a flow phantom using a bundle of capillaries
[16,17] one can never know for sure the flow velocity in
each vessel. The possibility therefore remains that the
flow is very high in a few capillaries, causing a positive
PD signal solely based on the high flow velocity of par-
ticles in these few capillaries.Table 3 Lowest detected flow velocity resulting in a
continuous positive power Doppler ultrasound signal
Machine 2,000 μm vessel 1,000 μm vessel 150 μm vessel
A 4 2.22 11.1
B 0.005 0.06 0.11
C 1 0.56 1.68
D 1 0.56 Not detected
E 0.5 0.33 Not detected
Flow velocity (mm/second).A study comparing Machines A and B (older versions
than in our study) on a 1,000 μm flow phantom has
been published in the past [12]. These older versions
of the machines were ranked regarding sensitivity the
same as in our study. However, in our study Machine B
detected a considerably lower flow compared with the
previous study: 0.06 mm/second in our study versus
1.3 mm/second in the previous. Machine A detected a
twofold lower flow in our study: 2.2 mm/second in our
study versus 3.9 mm/second in the earlier study.
Another study tested an earlier, single-element version of
Machine E (VisualSonics, Toronto, Canada Vevo 770;) on a
microvessel flow phantom with vessel dimensions similar
to ours (160 μm) [15]. In this microvessel, the Vevo 770 did
detect flows as low as 0.5 mm/second. In our study
Machine E did not detect any flow in the smallest vessel
(150 μm). A possible explanation for this higher sensitivity
for low flows could be that the Vevo 770 uses a mechanic-
ally steered probe with a single element, as opposed to the
array probe we used on Machine E in our study. In general,
the Doppler processing of a single-element system can be
very different from that of an array system.
Some observations raised discussion within our research
group. One of these discussions was about the very low
flows detected by Machine B in the 2,000 μm vessel. To
verify this finding the experiment was repeated several
times by two observers (DFTC and MvdV), which resulted
in similar findings. When setting the flow slightly lower,
the signal disappeared. Therefore, we think the measured
flow is correct. A possible explanation for this low limit is
that the PRF can be set to a very low level and the wall
filter cutoff frequency is probably also very low, in com-
bination with a good clutter suppression. However, in
in vivo situations, normal tissue or probe motion will pre-
vent detecting such extremely low flows.Table 4 Settings for detection of lowest flow velocity
in the 150 μm vessel
Machine Pulse repetition
frequency/velocity range
Wall filter Doppler frequency
A 1.3 cm/second Level 1 8 MHz
B 125 Hz Level 1 10 MHz
C 150 Hz 15 Hz R1a
Db 200 Hz Level 1 10 MHz
Eb 1,000 Hz Low 12.5 MHz
aActual frequency not displayed on this machine. bNo flow detected in this vessel.
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flow detected in the 1,000 μm vessel as compared with
the 2,000 μm vessel. A reason for this could be that the
flow velocity profile in the 1,000 μm vessel is shaped dif-
ferently, as compared with the 2,000 μm vessel, resulting
in a larger difference between average flow and maxi-
mum flow. This may even have been reinforced by com-
pression of the smaller vessel by the tissue-mimicking
material. This means the average flow velocity is actually
higher than estimated, since the calculation is quadra-
tically dependent on the microvessel diameter. If the
maximum velocity of the peak flow is slightly higher
than the wall filter cutoff, this results in a positive PD
signal. The peak flow may therefore be rather similar in
the 2,000 μm and the 1,000 μm vessels, but due to the
shape of the flow profile this corresponds to a lower
average flow velocity in the 1,000 μm vessel. While
the true value for the flow velocities may differ from
the calculated values, this difference is the same for all
machines, so the comparison between machines is still
valid per vessel.
A drawback of our study is that we have made assump-
tions on the capillary sizes and flow velocities in inflamed
joints based on papers published on healthy subjects and
periulcerous regions. This may not be entirely correct.
Therefore, at present it is crucial to ascertain the flow
velocities and capillary sizes in inflamed joints. With this
information the minimal flows that rheumatological US
machines need to be able to detect will be known.
Nonetheless, for a reliable and reproducible detection of
very low flows in inflamed joints, the choice of the US
machine and its settings seems very important. Caution
should be exercised when conducting a multi-machine
trial or when making treatment decisions based on PDUS.
Our flow phantom could be used to decide which US
machine to use both in clinical practice and in clinical
trials.
Conclusions
We created a flow phantom to test the sensitivity of US
machines to very low flows in small vessels. We found that
the sensitivity of the PD modalities was very different
between five US machines. Based on the results of our
study it would be advisable to standardise and validate US
machines both for rheumatological clinical practice and
for clinical trials. Our phantom could be used for this
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